Hyperhomocysteinemia, Folateo and B12 Vitamin in Iranian Patients with Acute Ischemic Stroke by Omrani, Hoseinali Qeilichnia et al.
 
1- Assistant Professor, Department of Neurology, Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran University 
of Medical Sciences, Tehran, Iran. 
2- Neurologist, Iranian Center of Neurological Research, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. 
3- PhD, Department of Epidemiology, Assistant Professor, Department of Epidemiology, School of Medicine, Tehran University of 
Medical Sciences, Tehran, Iran. 
Correspondence To: Ehsan Esmaili Shandiz, Email: ehsan_es79@yahoo.com 
 
  ARYA Atherosclerosis Journal 2011 (Fall); Volume 7, Issue 3  97 
Hyperhomocysteinemia, folateo and B12 vitamin in Iranian patients with acute 
ischemic stroke 
Hoseinali Qeilichnia Omrani









  BACKGROUND: The objective of this study was to evaluate the association of some factors such 
as serum levels of homocysteine, folate and B12 vitamin with stroke in acute ischemic stroke 
patients. 
 METHODS:  In this case control study, serum levels of homocysteine, folate and B12 vitamin in 
93 patients with acute ischemic stroke admitted to Imam Khomeini Hospital between 
September 2008 and January 2010, and 93 healthy controls were measured. Cerebrovascular 
risk factors including age, sex, hypertension, hyperlipidemia, smoking, diabetes mellitus, 
alcohol consumption, coronary artery disease and obesity were recorded. The results were 
compared between the case and control groups. 
 RESULTS: The mean ± standard deviation (SD) of fasting total homocysteine (tHcy) level in 
acute ischemic stroke patients was 20.58 ± 19.6 µmol/l, which was significantly higher than that 
of control group being  14.11 ± 9.5 µmol/l (P = 0.002). 39 (41.9%) stroke cases and 25 (26.8%) 
controls had hyperhomocysteinemia. There were no significant relationships between tHcy, 
folate and B12 vitamin levels with the above mentioned cerebrovascular risk factors except for 
smoking (p> 0.05). No significant difference in B12 vitamin and folate levels between patients 
and healthy controls were detected (P> 0.05). 
  CONCLUSION: Hyperhomocysteinemia is common in Iranian patients with acute ischemic 
stroke and might play a role as an independent risk factor in stroke. 
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Introduction 
Stroke is one of the leading causes of death in any 
population, and its prevention is a key strategy in 
reducing the rate of mortality and morbidity.  
  Several risk factors for stroke have been identified, 
which are the target of both primary and secondary 
preventive strategies. In 1969, McCully showed that 
elevated total Homocysteine (tHcy) levels were the 
cause of vascular diseases in children with inborn 
error of B12 vitamin metabolism. Since then, many 
studies have been performed to understand the effect 
of hyperhomocysteinemia in cerebrovascular 
diseases. While some studies indicated that tHcy is 
an independent risk factor, others didn’t confirm it.1  
  Hyperhomocysteinemia may cause endothelial 
dysfunction through oxidative stress, resulting in local 
thrombosis and subsequent ischemia. Another 
possible mechanism is the direct toxicity of 
homocysteine to blood vessels but there is no definite 
evidence to support either of these mechanisms.2 
  Several factors can influence tHcy level, among 
which the most important are the concentrations of B 
vitamins especially B12 and folate. Decreased serum 
levels of these factors result in high plasma tHcy levels.3 
  Since 1998, fortification of cereal grain flour 
products with folic acid was mandated in the United 
States to reduce the risk of neural tube defects in 
newborns. Supplementation with folate resulted in 
about 20-25% reduction in tHcy levels and 
cerebrovascular diseases. But some other trials such 
as Vitamin Intervention for Stroke Prevention (VISP) 
trial did not confirm it.3-4 
  The two strong determinants of fasting tHcy 
concentrations are age and sex, so that concentrations 
are higher in the elderly and greater in men than in 
women. In addition, there is a strong negative Hyperhomocysteinemia, folate and B12 vitamin in Iranian 
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correlation between estradiol levels and tHcy levels in 
postmenopausal women. Therefore, hormone therapy 
may lower tHcy levels. Some studies have shown that 
smokers have higher levels of tHcy than non-
smokers, independent of age or sex. Heavy coffee 
consumption is among the strongest lifestyle 
determinants of tHcy level. Also, both exercise and 
alcohol consumption are weak but significant 
determinants of homocysteine. Results of cross-sectional 
and population-based studies provided evidence that 
changes in several of these lifestyle factors, such as 
higher intake of B vitamins, cessation of smoking and 
abstention from coffee consumption, may lead to a 
reduction in tHcy concentration over time.5 
  The objective of this study was to determine 
whether there was a significant difference in tHcy, 
folate and B12 vitamin levels between stroke patients 
and healthy controls or not. 
Materials and Methods 
The approval of this study was obtained from the 
Ethnic Committee of Tehran University of Medical 
Sciences. In this case-control study, 93 consecutive 
ischemic stroke patients admitted to Imam 
Khomeini hospital between September 2008 and 
January 2010 were matched for age and sex with 93 
patients from the same hospital who were not 
affected with acute cerebrovascular diseases and did 
not have a history of stroke. 
  Informed consent was obtained from all stroke 
patients or their proxies and all healthy controls. The 
data (collected from case and control groups) 
included age, sex, weight, blood pressure and/or 
history of hypertension, diabetes mellitus, smoking, 
alcohol consumption, previous thrombotic episodes, 
and history of oral contraceptive products 
consumption in women. Patients who had conditions  
(or took certain medications) affecting tHcy levels, 
including renal insufficiency requiring dialysis, use of 
methotrexate, tamoxifen, L- DOPA, phenytoin or bile 
acid sequestrants were excluded  
  The antecubital site of either arm was used as the 
 
Table 1. Homocysteine, folate and B12 vitamin plasma values in cases* 
 N  Homocysteine  Folate  B12  vitamin 
Sex        
male 52  24.0538±  3.33  9.3942±  0.79  356.0192±32.7 
female 41  16.1951±  1.68  12.2537± 0.98  419.4146± 42.54 
Hypertension        
positive  74  21.3757± .33  10.6730± 0.72  366.0811± 26.54 
negative 19  17.5263±  2.56  10.5842± 1.34  453.6316± 94.14 
Diabetes        
Yes 26  23.6923±  5.13  12.2538± 1.40  237.09005± 46.49 
No 67  19.3851±  2.02  10.0343± 0.68  290.11512± 35.44 
Smoking        
Yes 25  28.3520±  6.33  10.6680± 1.31  217.30564± 43.46 
No 68  17.7353±  1.44  10.6500± 0.72  294.91953± 35.76 
Body mass index         
<27 24  19.3333±  4.96  11.3875± 1.43  402.2083± 46.13 
≥27 69  21.0261±  2.16  10.4000± 0.69  377.6232± 35.10 
Coronary artery disease         
Yes  30  25.6267± 4.60  9.4733± 1.15  197.43614± 36.04 
No 63  18.1905±  2.02  11.2175± 0.75  305.33575± 38.46 
OCP        
Yes 11  12.9545±  0.75  14.9091± 2.42  367.7273± 78.75 
No 30  21.6134±  2.28  10.0841± 0.62  386.1463± 30.75 
Alcohol        
Yes  5  31.0000± 10.02  10.6800± 3.75  486.0000± 37.39 
No 88  19.9977±  2.07  10.6534± 0.63  378.1705± 28.71 
*Patients were divided into subgroups characterized by different stroke risk factors   H. Qeilichnia Omrani, E. Esmaili Shandiz, M. Qabai, R. Chaman, H. Amiri Fard, M. Qaffarpoor 
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first choice for venipuncture and (after 12 hours of 
fasting) blood samples were obtained. The blood 
sample was centrifuged as soon as possible but could 
be kept on wet ice for up to 6 hours. Aliquots were 
prepared from the plasma, frozen for 12 hours and 
sent on dry ice the next shipping day to the central 
laboratory. tHcy, B12 vitamin and folate levels were 
determined by Elisa method. Hyperhomocysteinemia 
was defined as plasma tHcy levels above 14 µmol/l.2 
  The statistics in this study were done by SPSS 
(version 16.0) software. The comparison of serum 
levels of the main three factors between cases and 
controls was done using t test. 
Results 
A total of 93 patients with acute ischemic stroke (42 
women and 51men) and 93 healthy controls (42 
women and 51 men) were evaluated in this study. The 
mean age ± SD of the patients and controls were 62.2 
± 9.8 years and 61.8 ± 9.9 years, respectively (T = 0.32, 
P = 0.75). There was no significant difference between 
the mean age ± SD of male (62.0 ± 8.9) and female 
(62.7 ± 11.0) stroke patients (T = 0.69, P = 0.49).  
  Homocysteine, folate and B12 vitamin values in 
patient groups characterized by different stroke risk 
factors are shown in Table 1. Table 2 shows mean 
and standard deviation values of tHcy, B12 vitamin 
and folate serum levels. The mean ± SD level of 
fasting tHcy in acute ischemic stroke patients was 
20.58 ± 19.6 µmol/L, which was significantly higher 
than its level in controls 
  (14.11 ± 9.5 µmol/L) (P = 0.002). The median 
tHcy value in the case group was 14 µmol/l, while 
that of controls was 12.5 µmol/L. Thirty nine (41.9%) 
of 93 patients and 25 (26.8%) of 93 controls had 
hyperhomocysteinemia. Therefore, the relationship 
between tHcy levels and various subgroup 
characteristics was explored. There were no 
significant relationships between tHcy levels and most 
cerebrovascular risk factors including hypertension, 
hyperlipidemia, diabetes mellitus, alcohol 
consumption, coronary artery disease and obesity   
(P> 0.05). Neither was there any relationship between 
B12 vitamin and folate serum levels and the above 
mentioned risk factors. However, increased tHcy 
levels were found in smoking stroke patients   
(28.3 µmol/l) compared to non-smokers   
(17.7 µmol/l) (P= 0.02), (Table 3) 
  But, no significant relationships were detected 
between smokers and non-smokers in folate or B12 
vitamin serum levels. 
T test analysis of the tHcy, B12 vitamin and folate 
serum levels showed significant difference in tHcy 
levels between case and control groups. No 
significant differences in B12 vitamin and folate levels 
were found (P> 0.05). 
Discussion 
In this study 41% of patients had 
hyperhomocysteinemia. The main findings were as 
follows: (i) tHcy plasma levels in the acute phase of 
ischemic stroke (within 24 hours) were significantly 
higher than normal limits. (ii) No correlation between 
tHcy levels and stroke risk factors such as 
hypertension, hyperlipidemia,diabetes mellitus, alcohol 
consumption, coronary artery disease and obesity was 
observed. (iii) tHcy levels were significantly higher in 
smoker patients than in non-smokers. (iv) There was 
no relationship between B12 vitamin and folate serum 
levels with risk factors. (v) No significant differences in 
B12 vitamin and folate serum levels were observed 
between cases and controls. 
 
Table 2. Mean and standard deviation values of tHcy, B12 vitamin and folate serum levels in the two groups. 
   Homocysteine  B12  vitamin  Folate 
Cases 
Mean  20.5892 383.9677 10.6548 
SD 19.67253  275.22420  6.10491 
Controls 
Mean 14.1183  407.8495  9.4720 
SD 9.52514  228.95030  5.14231 
 
Table 3. Distribution of homocysteine levels in smoker and non-smoker stroke patients.  
 Mean  N  SD  Paired 
Differences 
Homocysteine 
Cases 20.5892  93  19.6725 
P=0.002 
Controls 14.1183  93  9.5251 
Folate 
Cases 10.6548  93  6.1049 
P=0.164  Controls 9.4720  93  5.1423 
B12 vitamin  Cases 383.9677  93  275.2242  P=0.498  Controls 407.8495  93  228.9503 
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  Parnetti et al. studied 161 consecutive patients 
with first-ever ischemic stroke classified using 
TOAST criteria and 152 neurologically healthy 
controls to assess the association between risk of 
stroke and increasing values of plasma homocysteine 
and the interaction between the mild 
hyperhomocysteinemia and conventional vascular risk 
factors. tHcy was elevated in all stroke subtypes: 
13.0±2.5  μmol/l in patients with cardioembolic 
disease, 13.9±5.4 μmol/l in those with small vessel 
diseases, 15.5±6.8 μmol/l in cases of undetermined 
stroke, and 17.8±13.5 μmol/l in patients with large 
vessel disease. Mean homocysteine level was 8.10 
μmol/l (SD=2.5) in controls. They suggested that 
mild hyperhomocysteinemia is confirmed to have a 
significant role as risk factor for all etiological 
subtypes of stroke.6 
  Although we didn’t sort our cases by their 
subtypes, we reached the same result as Parnetti et al. 
We both found that homocysteine is significantly 
higher in stroke patients than in controls, and it could 
be a risk factor for stroke. 
  In a prospective study, Perini et al. measured 
homocysteine plasma levels in stroke patients in 
order to investigate possible correlations of 
homocysteine with stroke severity and clinical 
outcome. The plasma level of Hcy was neither an 
independent determinant for stroke severity nor for 
patient’s outcome by the Barthel index. Mean plasma 
homocysteine of both ischemic and hemorrhagic 
stroke was significantly higher than in controls 
(P<0.05). Homocysteine in the acute phase of stroke 
was not associated with stroke severity or outcome. 
Elevated plasma homocysteine in the acute phase of 
stroke was associated with both ischemic and 
hemorrhagic stroke. Higher levels were associated 
with higher risk of small artery disease subtype of 
stroke. They failed to demonstrate that patients with 
high tHcy levels in the acute phase of ischemic stroke 
have a worse outcome. According to their study, 
hyperhomocysteinemia had no prognostic value.7 
 We  did assess tHcy plasma levels in the acute phase 
of ischemic stroke, but we did not evaluate the 
severity or outcome of stroke in this study. In spite of 
that, Perini et al.’s main finding was the same as that 
of our study; i.e., elevated plasma homocysteine in the 
acute phase of stroke. 
  In 2005, Haapaniemi et al.8 measured plasma 
tHcy levels in 102 consecutive stroke patients on 
admission and at 1 week, 1 month, and 3 months 
after stroke and only once in 102 control subjects. 
Compared with controls, plasma tHcy levels in 
patients were significantly lower on admission but 
not at later time points, with levels increasing by 
week and remaining at this level for 3 months. tHcy 
levels showed a positive correlation with age and a 
negative correlation with Mini-Mental State 
Examination (MMSE) scores. Plasma tHcy levels 
inversely correlated with plasminogen activator 
inhibitor. No correlation between tHcy levels and 
stroke severity, outcome, etiology, recurrence, infarct 
volume, CRP, or risk factors was observed. They 
proposed that this phenomenon was due to acute 
phase response reflecting increased synthesis of 
acute-phase proteins. However, they were unable to 
identify any correlation between CRP concentration 
in the acute stage of stroke and tHcy levels that 
corroborates earlier results.8 
  In this study, the relationship between stroke risk 
factors and mentioned serum factors were evaluated. 
Like Haapaniemi et al.,8 our research showed no 
correlation between tHcy level and most 
cerebrovascular risk factors. But, there was one 
difference: we found tHcy levels were significantly 
higher in smoker patients than in non-smokers.  
  All in all, we can conclude that elevated plasma 
homocysteine level might be an independent risk 
factor for ischemic stroke. But, because this study was 
a case control one, we could not rule out the 
possibility of acute phase response being responsible 
for the elevation of serum tHcy level in acute stroke 
patients. More prospective and population based 
studies are needed to define whether elevated plasma 
homocysteine level is an independent risk factor for 
cerebrovascular diseases or stroke by itself is the 
cause for hyperhomocysteinemia. 
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